Fragment-to-Lead Medicinal Chemistry Publications in 2017

Paul N Mortenson; Daniel A Erlanson; Iwan J P de Esch; Wolfgang Jahnke; Christopher N Johnson

doi:10.1021/acs.jmedchem.8b01472

Fragment-to-Lead Medicinal Chemistry Publications in 2017

J Med Chem. 2019 Apr 25;62(8):3857-3872. doi: 10.1021/acs.jmedchem.8b01472. Epub 2018 Nov 21.

Authors

Paul N Mortenson¹, Daniel A Erlanson², Iwan J P de Esch³, Wolfgang Jahnke⁴, Christopher N Johnson¹

Affiliations

¹ Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , Cambridge CB4 0QA , United Kingdom.
² Carmot Therapeutics Inc. , 740 Heinz Avenue , Berkeley , California 94710 , United States.
³ Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS) , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ , Amsterdam , The Netherlands.
⁴ Chemical Biology and Therapeutics , Novartis Institutes for Biomedical Research , 4002 Basel , Switzerland.

PMID: 30462504
DOI: 10.1021/acs.jmedchem.8b01472

Abstract

This Miniperspective is the third in a series reviewing fragment-to-lead publications from a given year. Following our reviews for 2015 and 2016, this Miniperspective provides tabulated summaries of relevant articles published in 2017 along with some general observations. In addition, we discuss insights obtained from analysis of the combined data set of 85 examples from all three years of publications.

Publication types

Review

MeSH terms

Chemistry, Pharmaceutical* / trends
Drug Discovery / methods*
Drug Discovery / trends
Drug Evaluation, Preclinical / methods